Septerna (NASDAQ:SEPN) Sets New 1-Year High – Here’s What Happened

Septerna, Inc. (NASDAQ:SEPN)’s share price reached a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $37.50 and last traded at $36.57, with a volume of 301521 shares traded. The stock had previously closed at $34.85.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the stock. Zacks Research upgraded shares of Septerna from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 24th. Stifel Nicolaus began coverage on Septerna in a report on Friday, May 1st. They set a “buy” rating and a $43.00 price target for the company. Truist Financial upped their price objective on Septerna from $34.00 to $35.00 and gave the stock a “buy” rating in a research report on Wednesday, March 11th. Wall Street Zen downgraded Septerna from a “buy” rating to a “hold” rating in a report on Saturday, March 14th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $60.00 target price on shares of Septerna in a research report on Tuesday, March 10th. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $45.78.

Septerna Stock Performance

The stock’s 50-day moving average is $28.54 and its 200 day moving average is $27.16. The stock has a market capitalization of $1.65 billion, a PE ratio of -45.15 and a beta of 2.39.

Septerna (NASDAQ:SEPN) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.23. Septerna had a negative net margin of 49.88% and a negative return on equity of 12.72%. The firm had revenue of $26.52 million for the quarter, compared to analyst estimates of $16.98 million. Analysts expect that Septerna, Inc. will post -1.57 earnings per share for the current year.

Insider Transactions at Septerna

In related news, insider Samira Shaikhly sold 6,250 shares of the firm’s stock in a transaction that occurred on Friday, June 12th. The stock was sold at an average price of $35.08, for a total transaction of $219,250.00. Following the transaction, the insider owned 793 shares in the company, valued at $27,818.44. This trade represents a 88.74% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, COO Elizabeth Bhatt sold 4,000 shares of Septerna stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $24.34, for a total value of $97,360.00. Following the transaction, the chief operating officer directly owned 174,209 shares in the company, valued at approximately $4,240,247.06. This trade represents a 2.24% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 27,983 shares of company stock worth $842,957 in the last quarter. Insiders own 5.80% of the company’s stock.

Institutional Investors Weigh In On Septerna

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Group One Trading LLC grew its position in shares of Septerna by 111.8% during the fourth quarter. Group One Trading LLC now owns 944 shares of the company’s stock worth $26,000 after acquiring an additional 8,955 shares during the last quarter. Global Retirement Partners LLC purchased a new stake in Septerna in the 4th quarter valued at $35,000. Russell Investments Group Ltd. purchased a new stake in Septerna in the 3rd quarter valued at $36,000. Caitong International Asset Management Co. Ltd acquired a new stake in Septerna during the 4th quarter worth $53,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in Septerna during the 4th quarter worth $61,000.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.